Syndecans, a new perspective for Pancreatic Ductal Adenocarcinoma (PDAC)


Bertran Mas, Juan  


Ductal Adenocarcinoma of the Pancreas (ADP) is a fatal disease characterized by molecular alterations. Patients rarely present symptoms in the early stages of the disease, preventing a rapid diagnosis. This is the main reason for the poor prognosis of the PDAC. Risk factors include age, sex, smoking, obesity, genetic factors (family history), chronic pancreatitis, diabetes, and others. Syndecans are a family of proteoglycans that are involved in many physiological processes, especially cell proliferation, adhesion, and migration. Their physiological presence is related to many types of cells and their interactions enhance many pathways. Most syndecan-related associations involve the Extracellular Matrix, Growth Factors, and Integrins, acting as biochemical, physical, and mechanical transducers. Normally syndecans act as cell membrane proteins, but the external domain can be released from the cell surface through the action of Metal loproteins, converting syndecanes into soluble molecules, capable of binding distant molecules such as ECM molecules, or even the receptors of Growth Factors and the Integrins of other cells. All these processes are necessary for the development of tumors; That is why this work reviews these types of proteoglycans and their roles in tumorigenesis. Among them, syndecà-2 is the most relevant in the survival of ADP, it has a direct link between the ECM and the actin cytoskeleton and improves the activation of the Ras protein to induce perineural invasion in this type of cancer. It also functions as an angiogenic element in endothelial cells, providing more facilities for cell proliferation and propagation. This work relates the activity of syndecans with ADP and illustrates the possibility of targeting new future cancer treatments.



Semino Margrett, Carlos  


IQS SE - Undergraduate Program in Biotechnology